We are pleased to announce the release of the new edition of Px Wire, AVAC’s quarterly update on HIV prevention research—a one-stop source for information on biomedical HIV prevention research worldwide. Download the current issue at avac.org/pxwire.
Highlights in this issue include an update of the ongoing discussions around the follow-up of the CAPRISA 004 trial finding that 1% tenofovir gel reduces a women’s risk of acquiring HIV by 39 percent overall. What additional trials are being considered and why? Who will map the next steps?
This issue also briefly touches on the increasing discussions of “treatment as prevention” in reference to the possible use of antiretroviral treatment to reduce the risk of HIV transmission.
As usual, this latest issue of Px Wire includes an updated center poster with a comprehensive map and timeline of efficacy trials of new biomedical HIV prevention worldwide and a calendar of upcoming events. Also, as noted in the Coming Up section, results from the iPrEx PrEP trial are anticipated in the coming months, and AVAC will soon publish Vol. 3 of its Cascade of Hope and Questions series.
Additional resources including the Px Wire archive, information about subscribing, reprint requests and bulk orders can be found at avac.org/pxwire.
As always, comments are most welcome.